Best Life Sciences Companies in Cologne, Germany
The 32 best Life Sciences companies in Cologne, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cevec Pharmaceuticals.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Cologne
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cevec Pharmaceuticals Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28M | 63 mo ago | Acquired | 39 | 2001 | — | 208 patents Viral vector production platforms and engineered cell lines for gene therapy therapeutics | — |
| 2 | DISCO Pharmaceuticals Developer of target-directed therapeutic modalities for the treatment of cancer 40Growth top 28%Funding top 36%News top 36%Talent top 38% All 9 signals ▾Growthtop 28% Fundingtop 36% Newstop 36% Talenttop 38% Partnerstop 40% Moattop 42% Globalbottom 39% Marketbottom 35% Techbottom 17% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $22M | 10 mo ago | Seed | — | 2022 | Johannes Heuckmann Chief Operating Officer (COO) and founder | — | — |
| 3 | Ayoxxa Biosystems Developer of a platform for multiplex protein analysis | $19M | 118 mo ago | Deadpooled | 40 | 2010 | — | 4 patents Decodable microarray platforms for nucleic acid detection and reference area encoding | — |
| 4 | amaxa biosystems Amaxa Biosystems develops and commercializes gene transfer technologies and products. | $12M | 304 mo ago | Acquired | 160 | 1998 | — | — | — |
| 5 | MELAGENIX Developer of molecular diagnostic tests to detect skin cancer | $9M | 80 mo ago | Series A | 9 | 2017 | Daniel Janowski Co-Founder & CPO | — | — |
| 6 | Nexigen Developer of therapies for oncological indications | $6M | 185 mo ago | Deadpooled | 10 | 2007 | — | 23 patents Patents concentrated in chemistry & materials | — |
| 7 | New Oncology Provider of pharmacogenomics tests for cancer | $6M | 132 mo ago | Acquired | 30 | 2012 | — | — | — |
| 8 | PROSION Developer of precision medicine technology for cancer treatment | $6M | 55 mo ago | Funding Raised | 10 | 2020 | Mutlu Yonel Co-Founder | — | — |
| 9 | InfanDx Developer of in-vitro diagnostic products for acute and critical care conditions in newborns | $5M | 55 mo ago | Series A | 14 | 2010 | — | 24 patents Metabolic biomarker panels for diagnosing neonatal encephalopathy, asphyxia, and stroke. | — |
| 10 | Cellex Developer of stem cells for cancer treatment | $2M | 200 mo ago | Funding Raised | 127 | 2001 | Carla Kreissig Co-CEO | — | — |
| 11 | Niostem Provider of smart wearable device to regrow hair | $2M | 57 mo ago | Seed | 9 | 2019 | Emil Aliev Co-Founder | — | — |
| 12 | DESINO Wheelchair with patented seating system | $534K | 131 mo ago | Deadpooled | — | 2012 | Thyl Junker Co-Founder & Director | 6 patents Active wheelchair seat actuation mechanisms and manual wheelchair propulsion systems | — |
| 13 | Sividon Molecular breast cancer assays | $110K | 130 mo ago | Acquired | 27 | 2010 | Christoph Petry Founder | — | — |
Top 12 Life Sciences companies in Cologne
#1
Seed · Cologne, North Rhine Westphalia · founded 2022$21.9Mraised▾
Developer of target-directed therapeutic modalities for the treatment of cancer. The company specializes in mapping the surfaceome of cancer cells and develop first-in-class cancer drugs. It identifies proteins and protein communities across the entire cancer cell surface addressing the need for target candidates for both mono- and bi-specific antibodies.
- Dec 2025Seed$41.9M
- Jan 2024Seed$21.9M
#2
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees$28.4Mraised▾
Provider of glyco-optimized human cell lines and gene therapy vectors using proprietary cell expression system. The company has ELEVECTA technology for AAV manufacturing, CAP Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Provides the CAP GT expression platform, a scalable production system for gene therapy vectors. Also offers cell line development and protein expression services.
- Jul 2021Series E—
- Apr 2019Series D—
- Jul 2015Series C$4.9M
- Oct 2012Series C$3.6M
#3
Deadpooled · Cologne, North Rhine Westphalia · founded 2010 · 40 employees$18.5Mraised▾
Ayoxxa Biosystems developed a technology platform for multiplexed protein analysis. The company's proprietary platform includes Lunaris BioChip that is used to identify and quantify proteins, including markers for cancer, allergies, cardiovascular or infectious diseases. It can be useful in biomedical research, pharmacological screening, and preclinical diagnostics development. The company also offers disease-specific detection kits such as 6-Plex Cytokine Kits to analyze biomarkers that are important in inflammation and in immune regulation.
- Jan 2017Grant (prize money)$21.9K
- May 2015Grant (prize money)$681.5K
- Dec 2014Series B$2.9M
- Jun 2014Series B$12.3M
#4
Funding Raised · Cologne, North Rhine Westphalia · founded 2020 · 10 employees$5.5Mraised▾
Developer of precision medicine technology for cancer treatment. It has developed a ProM (proline-rich-motif)-platform to develop ProM-based inhibitors to target undruggable sites of Breast cancer, pancreatic cancer, Alzheimer's disease, and others.
- Apr 2022Grant (prize money)$2.7M
- Nov 2021Grant (prize money)$2.8M
#5
Series A · Cologne, North Rhine Westphalia · founded 2010 · 14 employees$4.7Mraised▾
Developer of in-vitro diagnostic products for acute and critical care conditions in newborns. The product HypoxE test is used for the early identification of newborns suffering from perinatal asphyxia due to oxygen deficit during birth, the prognosis of hypoxic-ischemic encephalopathy, and brain injuries.
- Mar 2022Series A—
- Jul 2021Series A$4.7M
#6
Series A · Cologne, North Rhine Westphalia · founded 2017 · 9 employees$8.9Mraised▾
Nenacare has developed molecular diagnostic tests to detect skin cancer. The molecular diagnostic test developed is called MELAGENIX, an RT-PCR-based assay (clinical trial stage I-III patients), used to assess (AJCC staging) and provide tumor-specific information on melanoma patients that is required to make improved treatment decisions.
- Mar 2020Series A$8.9M
#7
Acquired · Cologne, Nordrhein-Westfalen · founded 1998 · 160 employees$11.6Mraised▾
Amaxa Biosystems develops and commercializes gene transfer technologies and products.
#8
Seed · Cologne, North Rhine Westphalia · founded 2019 · 9 employees$1.9Mraised▾
Provider of smart wearable device to regrow hair. The company has developed nio1 a smart wearable device to combat pattern baldness that uses low-level bioelectrical stimulation to the scalp to trigger the natural growth cycle of the body.
- Jan 2022Seed$1.9M
#9
Acquired · Cologne, North Rhine Westphalia · founded 2012 · 30 employees$5.7Mraised▾
Provider of pharmacogenomics tests for cancer. The company uses next-generation sequencing (NGS) for variant detection of two gene panels: NeoPlus, which uses FFPE and other solid tissue samples, and NEOLiquid for the detection of circulating cell-free DNA.
- Oct 2015Series D$5.7M
- Mar 2015Series D—
#10
Deadpooled · Cologne, North Rhine Westphalia · founded 2007 · 10 employees$5.9Mraised▾
Nexigen is developing drugs with a focus on oncological indications. They have developed a proprietary screening technology, NexiScreen, which identifies disease relevant protein-protein interactions and detects target interacting peptides. Their lead candidate, NexC1004, which acts through the hedgehog signaling pathway. The candidate is being investigated for various malignancies.
- Jun 2011Series A$5.9M
#11
Funding Raised · Cologne, North Rhine Westphalia · founded 2001 · 127 employees$2Mraised▾
Cellex is developing stem cells for cancer treatment in collaboration with GEMoaB Monoclonals. They have developed their universal CAR technology (UniCAR) where immune cells are taken and modified with a surface protein known as chimeric antigen receptor (CAR-T).
- Mar 2010Grant (prize money)$2M
#12
Deadpooled · Cologne, North Rhine Westphalia · founded 2012$534Kraised▾
DESINO has developed wheelchair offering dynamic seating and manual drive. The products developed are medius, radius, and sinus. The patenting seating system which provides oscillating movements to mobilize the spine & muscles to relieve back pain. The manual dual is carried out by the movements of arms for handrim propulsion with an lever propulsion making the patient travel longer distances. The wheelchair can be used to ride on slopes by using the 11-speed gearshift.
- Dec 2015Series A$534K
- Mar 2014Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Cologne researches in biotechnology
- University of Cologne13
- University Hospital Cologne3
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.